Last reviewed · How we verify

NCT06695468

Efficacy and Safety of Adding Dexmedetomidine to Levobupivacaine in Rectus Sheath Block Compared to Quadratus Lumborum Block in Patients Undergoing Lower Abdominal Cancer Surgery: A Randomized Clinical Trial

Not yet recruiting Phase 4 Last updated 19 November 2024
What this trial tests

Phase 4 trial testing Levobupivacaine in Abdominal Cancer Surgery in 122 participants. Not yet recruiting.

Timeline
1 December 2024
Primary endpoint
1 December 2026
1 January 2027

Quick facts

Lead sponsorAssiut University
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment122
Start date1 December 2024
Primary completion1 December 2026
Estimated completion1 January 2027

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

18 and older, any sex, with Abdominal Cancer Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgical trauma activates numerous receptors leading to severe postoperative pain. Seventy to seventy-five percent of the pain is somatic, originating from the anterior abdominal wall, and it often persists for 72 hours after open surgery. The objective of this study is to compare the efficacy and safety of adding dexmedetomidine to Levobupivacaine in rectus sheath block with quadrates lumborum block in patients undergoing lower abdominal cancer surgeries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levobupivacaine

Trials testing the same drug.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06695468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing